M. Keohan

C. Obasaju, P. Jänne, A. Wozniak, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.

C. Obasaju, P. Jänne, D. Mintzer, 2005, Clinical lung cancer.

Combined Resection, Intraperitoneal Chemotherapy, and Whole Abdominal Radiation for the Treatment of Malignant Peritoneal Mesothelioma

Shing M. Lee, J. Chabot, M. Hesdorffer, 2008, American journal of clinical oncology.

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

A. D. Van den Abbeele, G. Demetri, J. Yap, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma

S. Singer, C. Kelly, W. Tap, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

Narasimhan P. Agaram, Narasimhan P Agaram, L. Qin, 2022, Nature Communications.

Transarterial Chemoembolization with Doxorubicin Eluting Beads for Extra-Abdominal Desmoid Tumors: Initial Experience

J. Erinjeri, M. Gounder, A. Crago, 2022, CardioVascular and Interventional Radiology.

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

R. Carlson, S. D'Angelo, J. Erinjeri, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome

L. Qin, C. Antonescu, S. D'Angelo, 2020, Clinical Cancer Research.

Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome

C. Antonescu, S. Singer, J. Guillem, 2017, Annals of Surgical Oncology.

A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST).

L. Qin, C. Antonescu, S. D'Angelo, 2015 .

A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.

L. Qin, S. D'Angelo, S. Singer, 2015, The oncologist.

Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial

G. Demetri, R. Maki, G. Schwartz, 2008 .

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma

L. Qin, S. D'Angelo, R. Maki, 2015, Sarcoma.

Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060)

R. Maki, G. Schwartz, S. Schuetze, 2007 .

Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma

C. Antonescu, S. D'Angelo, W. Tap, 2015, Oncology.

Radiation Therapy in the Treatment of Cutaneous Angiosarcoma of the Head and Neck

J. Shah, N. Lee, D. Spratt, 2013 .

Early metabolic response to continuous daily dosing of sunitinib in soft tissue sarcomas (STS) other than GIST using FDG- PET

G. Demetri, J. Yap, R. Maki, 2008 .

PD-L1 expression and immune infiltrates in sarcoma.

Narasimhan P. Agaram, L. Qin, S. D'Angelo, 2014 .

P 16 Loss andMitotic Activity Predict Poor Survival in Patients with Peritoneal MalignantMesothelioma

A. Borczuk, C. Powell, J. Chabot, 2005 .

Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center

C. Antonescu, S. D'Angelo, S. Singer, 2022, Journal for ImmunoTherapy of Cancer.

Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas

J. Blay, C. Antonescu, F. Bertucci, 2012, Cancer.

Advances in the systemic treatment of cutaneous sarcomas.

J. Luke, M. Keohan, 2012, Seminars in oncology.

Peritoneal mesothelioma

J. Chabot, M. Keohan, R. Taub, 2000, Current treatment options in oncology.

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

L. Qin, C. Antonescu, L. Schwartz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes.

L. Qin, M. Ladanyi, C. Antonescu, 2020, JCO precision oncology.

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

L. Qin, C. Antonescu, S. Singer, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

J. Blay, G. Demetri, M. von Mehren, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

Paul A Meyers, Laurence H Baker, J Kyle Wathen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.

L. Qin, C. Antonescu, S. Singer, 2016, JAMA oncology.

Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas.

Narasimhan P. Agaram, L. Qin, M. Arcila, 2015, European journal of cancer.

Factor analysis validates the cluster structure of the dendrogram underlying the Multidimensional Affect and Pain Survey (MAPS) and challenges the a priori classification of the descriptors in the McGill Pain Questionnaire (MPQ)

W. Clark, J. Kuhl, M. Keohan, 2003, Pain.

Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

Narasimhan P. Agaram, N. Socci, N. Schultz, 2021, Nature Communications.

Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols.

W. Shi, S. Singer, S. Wolden, 2013, International journal of radiation oncology, biology, physics.

Extraskeletal myxoid chondrosarcoma

C. Antonescu, C. Fisher, S. Singer, 2008, Cancer.

HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome

L. Qin, C. Antonescu, C. Kelly, 2020, Clinical Cancer Research.

A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.

L. Qin, C. Antonescu, R. Maki, 2018, The oncologist.

Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab

L. Qin, C. Antonescu, J. Erinjeri, 2016, Clinical Cancer Research.

Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib

J. Blay, C. Antonescu, B. Bui, 2012, Annals of Surgical Oncology.

Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor

N. Schultz, L. Qin, M. Berger, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor

L. Qin, C. Antonescu, S. Singer, 2019, The oncologist.

A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor

L. Qin, C. Antonescu, S. Singer, 2018, Investigational New Drugs.

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.

L. Qin, C. Antonescu, S. Singer, 2020, JAMA oncology.

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.

G. Schwartz, W. Tap, B. V. Van Tine, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST).

L. Qin, C. Antonescu, R. Maki, 2011, Journal of Clinical Oncology.

Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis

C. Antonescu, S. Singer, R. Maki, 2010, Clinical Cancer Research.

Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)

C. Antonescu, S. Singer, R. Maki, 2010, Cancer.

Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.

V. Miller, S. Millis, R. Maki, 2017 .

A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma

A. Troxel, E. Bagiella, M. Hesdorffer, 2003, Cancer.

Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival.

C. Antonescu, S. Salas, J. Coindre, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of sorafenib in patients with desmoid-type fibromatosis.

L. Qin, R. Maki, G. Schwartz, 2016 .

Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.

Danila Valmori, Philippe Guillaume, Susan Talbot, 2002, The Journal of clinical investigation.

Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.

L. Qin, C. Antonescu, S. Singer, 2019, Journal of Clinical Oncology.

Chemotherapy in clear cell sarcoma

Robin L. Jones, C. Antonescu, C. Fisher, 2011, Medical oncology.

DNA damage response pathway alterations and clinical outcome in leiomyosarcoma.

L. Qin, C. Kelly, W. Tap, 2019, Journal of Clinical Oncology.

Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab.

Helen X. Chen, M. Lacouture, G. Abou-Alfa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.

Narasimhan P. Agaram, L. Qin, G. Schwartz, 2015, Human pathology.

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma

R. Maki, G. Schwartz, I. Lowy, 2013, Sarcoma.

SSX antigens as tumor vaccine targets in human sarcoma.

Yao-Tseng Chen, L. Old, D. Valmori, 2003, Cancer immunity.

A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft-Tissue Sarcomas

R. Maki, M. Keohan, D. D’Adamo, 2006, Sarcoma.

Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma

A. Shoushtari, W. Tap, M. Gounder, 2016, Sarcoma.

Phase II study of intravenous TZT‐1027 in patients with advanced or metastatic soft‐tissue sarcomas with prior exposure to anthracycline‐based chemotherapy

R. DeJager, Shreyaskumar R Patel, D. Rushing, 2006, Cancer.

Complete metabolic response to therapy of hepatic epithelioid hemangioendothelioma evaluated with 18F-fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography

O. Basturk, O. Schillaci, D. Klimstra, 2018, Medicine.

Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.

J. Erinjeri, G. Schwartz, A. Shoushtari, 2014 .

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma

S. Steinberg, J. Doroshow, A. Chen, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma

Zhezhen Jin, M. Hesdorffer, M. Keohan, 2008, Sarcoma.

A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma.

L. Qin, C. Antonescu, S. Singer, 2019, Clinical Cancer Research.

ClinicalStudy Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma

Herbert Irving Pavilion, Zhezhen Jin, M. Hesdorffer, 2005 .

Activity of sorafenib in radiation-associated breast angiosarcomas harboring MYC and FLT4 amplifications.

C. Antonescu, S. Singer, G. Schwartz, 2012 .

Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060

R. Maki, S. Schuetze, J. Wright, 2008 .

Phase II study of the HSP 90-inhibitor BIIB 021 in gastrointestinal stromal tumors

Adamo, C. Antonescu, R. Maki, 2012 .

Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma.

L. Qin, C. Antonescu, S. Singer, 2012 .

Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy

G. Demetri, S. Schuetze, M. Mehren, 2004 .

Predictors of overall survival in patients diagnosed with desmoplastic small round cell tumor (DSRCT).

L. Qin, A. Shoushtari, W. Tap, 2014 .

Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial.

P. Thall, R. Benjamin, L. Baker, 2004, Journal of Clinical Oncology.

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

L. Qin, C. Antonescu, S. Singer, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)

C. Antonescu, S. Singer, R. Maki, 2010, Cancer.

Pilot study of NKTR214 and nivolumab in patients with sarcomas.

Narasimhan P. Agaram, L. Qin, J. Erinjeri, 2019, Journal of Clinical Oncology.

A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma.

L. Qin, C. Antonescu, S. Singer, 2018 .

A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma.

L. Qin, C. Antonescu, S. Singer, 2023, Clinical Cancer Research.

Risk factors associated with ifosfamide (IFOS)-induced encephalopathy in patients (pts) with metastatic (Met) sarcoma (Sarc).

L. Qin, W. Tap, M. Gounder, 2017 .